Active, not recruitingPhase 3NCT05133531
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Studying Paroxysmal nocturnal hemoglobinuria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Ravulizumab(drug)
- Enrollment
- 202 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- The Oncology Institute of Hope & Innovation, Whittier, California, United States
- Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo André, São Paulo, Brazil
- A Beneficencia Portuguesa de Sao Paulo, BP Mirante, São Paulo, Brazil
- Casa de Saude Santa Marcelina, São Paulo, Brazil
- Toronto General Hospital, Toronto, Ontario, Canada
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Hospital Pablo Tobon Uribe, Medellín, Antioquia, Colombia
- George Papanikolaou Hospital, Thessaloniki, Greece
- Semmelweis University, Budapest, Hungary
- Malabar Cancer Center, Kerala, Kannur, Kerala, India
- Amrita Institute of Medical Sciences (AIMS) and Research Centre Aims, Kochi, Kerala, India
- K J Somaiya Super Specialty Hospital & Research Centre, Mumbai, Maharashtra, India
- Rajiv Gandhi Cancer Institute & Research Center (RGCIRC) - Rohini Campus, New Delhi, National Capital Territory of Delhi, India
- Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, Punjab, India
- King George Hospital, Lucknow, Uttar Pradesh, India
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05133531 on ClinicalTrials.govOther trials for Paroxysmal nocturnal hemoglobinuria
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07457151Danicopan PMS in KoreaAstraZeneca
- RECRUITINGPHASE3NCT07154745A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRegeneron Pharmaceuticals
- RECRUITINGPHASE1NCT07462780A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy ParticipantsShenzhen Kangzhe Biotechnology Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07470762Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaJiangsu Hansoh Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07187401A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 InhibitorRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry DataAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07229235REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT06934967Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsNovartis Pharmaceuticals